NervGen Pharma Corp. Common stock

NGEN XNAS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

210M

Short interest (May 15)

1.9%

Net Short (Jun 03 ): 0.0%

Borrow Fee

1.20%

↑ 0.5%

Available Shares

↑ 470.9%

Price Chart

Company Overview

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Company Info

Exchange: NASDAQ

CIK: 0001751912

Asset Type: CS

Market Data

Market Cap: $212,406,272

Employees: 9

Status: Active

Short Interest

Current Borrow Fee 1.20%

Range: 1.16% - 1.20%

Available Shares 3M

Range: 2.6M - 3.1M

Recent Changes

Fee Change: ↓ 1.9%

Available Change: ↓ 6.2%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime